OncoMatch/Clinical Trials/NCT05487391
A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.
Is NCT05487391 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments for carcinoma, non-small-cell lung.
Treatment: QL1706 · Vinorelbine Tartrate · Paclitaxel · Cisplatin · Carboplatin · Pemetrexed — The purpose of this study is to evaluate the efficacy and safety of QL1706 combined with platinum-based chemotherapy versus placebo combined with platinum-based chemotherapy in adjuvant treatment of stage II-IIIB NSCLC without EGFR-sensitizing mutations and ALK fusions after complete surgical resection.The subjects were randomly divided into two groups according to 1:1, with about 316 subjects in the experimental group and the control group.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR wild-type
Non-squamous NSCLC subjects without EGFR-sensitizing mutation or ALK fusion gene.
Required: ALK wild-type
Non-squamous NSCLC subjects without EGFR-sensitizing mutation or ALK fusion gene.
Disease stage
Required: Stage II, IIIA, IIIB
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: neoadjuvant chemotherapy
Previous treatment with neoadjuvant/adjuvant chemotherapy
Cannot have received: adjuvant chemotherapy
Previous treatment with neoadjuvant/adjuvant chemotherapy
Cannot have received: immune checkpoint inhibitor
Previous treatment with ... immune checkpoint inhibitor therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify